SineuGene

Executive Summary

SineuGene is a Shanghai-based biotechnology company pioneering gene therapies for neurological disorders and rare diseases. Founded in 2018, the company specializes in developing novel adeno-associated virus (AAV) vectors designed to deliver genetic payloads to the central nervous system. By leveraging proprietary capsid engineering and gene expression optimization, SineuGene aims to create one-time, transformative treatments for conditions with high unmet medical need. Its preclinical pipeline targets severe neurodegenerative and rare genetic disorders, where current treatment options are limited or nonexistent. The company's approach addresses key challenges in CNS gene therapy, including crossing the blood-brain barrier and achieving durable, safe expression. Operating at the preclinical stage, SineuGene is focused on advancing its lead programs toward Investigational New Drug (IND)-enabling studies and eventual clinical trials. The company benefits from China's growing biotech ecosystem and government support for gene therapy innovation. However, it faces significant technical and regulatory hurdles, including vector immunogenicity, manufacturing scalability, and clinical validation. Key risks include competition from established gene therapy players and the inherent uncertainty of early-stage development. If successful, SineuGene could provide life-altering therapies for patients with devastating neurological conditions, offering durable efficacy from a single administration.

Upcoming Catalysts (preview)

• H2 2026IND Filing for Lead Neurological Program65% success
• 2026Series B/C Financing Round70% success
• TBDResearch Collaboration or Licensing Deal50% success